Search Results

You are looking at 51 - 60 of 167 items for :

  • "BRAF mutation" x
  • Refine by Access: All x
Clear All
Full access

Shailender Bhatia and John A. Thompson

V600R). 25 The absolute and relative frequencies of the different mutations of BRAF are age-dependent, with an inverse relationship between age and BRAF mutation rate and a higher proportion of V600K mutations in older patients. 26 Earlier

Full access

Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Dominick DiMaio, Ryan C. Fields, Martin D. Fleming, Brian Gastman, Rene Gonzalez, Valerie Guild, Douglas Johnson, Richard W. Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. Olszanski, Patrick Ott, Aparna Priyanath Gupta, Merrick I. Ross, April K. Salama, Joseph Skitzki, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Anita Engh

with single-agent ipilimumab. Both these trials also showed substantially increased toxicity with immune checkpoint combination therapy versus monotherapy. Anti–PD-1 Therapy in Patient Subpopulations: BRAF Mutation Status: Subgroup analyses in the

Full access

Sanam Loghavi, Mark J. Routbort, Keyur P. Patel, Rajyalakshmi Luthra, Wei-Lien Wang, Russell R. Broaddus, Michael A. Davies, and Alexander J. Lazar

cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status . J Clin Oncol 2011 ; 29 : 2011 – 2019 . 26. Hutchins G Southward K Handley K . Value of mismatch repair, KRAS, and BRAF mutations in predicting

Full access

Robert I. Haddad, Christian Nasr, Lindsay Bischoff, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney Goldner, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Bryan McIver, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Rebecca Sippel, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Alyse Johnson-Chilla, Karin G. Hoffmann, and Lisa A. Gurski

with BRAF mutation–positive DTCs that are locally recurrent, advanced, and/or metastatic, are not surgically resectable, are not amenable to RAI, and are progressing and/or symptomatic (see PAP-9, page 1433). The decision was made to not specify BRAF

Full access

Axel Grothey and Alan P. Venook

from the IDEA study for adjuvant treatment of colon cancer. advanced disease. Tumors should be evaluated for KRAS, NRAS , and BRAF status, either individually or as part of a next-generation sequencing panel. KRAS and BRAF mutations are

Full access

Lindsey M. Charo, Adam M. Burgoyne, Paul T. Fanta, Hitendra Patel, Juliann Chmielecki, Jason K. Sicklick, and Michael T. McHale

neurodegenerative dementia 22 but are not well-associated with human cancer. According to several studies, approximately 1% of GISTs possess BRAF mutations, which are most often canonical V600E seen in other tumor types, including melanoma and colon cancer. 3

Full access

Anastasia Drobysheva, Laura J. Klesse, Daniel C. Bowers, Veena Rajaram, Dinesh Rakheja, Charles F. Timmons, Jason Wang, Korgun Koral, Lynn Gargan, Erica Ramos, and Jason Y. Park

); only 1 of the 17 patients had a BRAF mutation, and no patients had mutations in HRAS, KRAS, NRAS , or FGFR1 on targeted analysis. 18 Frequent MAPK pathway activation through fusion and nonfusion mutations has been recognized as a potential target

Full access

Kristin K. Deeb, Jakub P. Sram, Hanlin Gao, and Marwan G. Fakih

BRAF mutations in colorectal cancer have been incorporated into oncology practice for cetuximab and panitumumab therapy since 2008. 26 High-throughput technologies using NGS that enable massively parallel sequencing of nucleic acid (DNA and RNA) at a

Full access

Jeremy D. Kratz, Nataliya V. Uboha, Sam J. Lubner, Daniel L. Mulkerin, Linda Clipson, Yanyao Yi, Menggang Yu, Kristina A. Matkowskyj, Noelle K. LoConte, and Dustin A. Deming

anti-EGFR therapy in patients with tumors harboring KRAS, NRAS , and BRAF mutations, which are commonly enriched within the right-sided primary population. 25 – 27 When stratified for sidedness, prospective targeted sequencing panels have revealed

Full access

Daniel G. Coit and Anthony J. Olszanski

median overall survival was 13.6 versus 9.7 months, respectively ( P <.001). 11 , 12 Up to 50% of patients with the BRAF mutation show a response to this drug; however, the typical duration of response is approximately 6 months, due to the emergence